GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altamira Therapeutics Ltd (NAS:CYTO) » Definitions » Asset Impairment Charge

Altamira Therapeutics (Altamira Therapeutics) Asset Impairment Charge : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Altamira Therapeutics Asset Impairment Charge?

Altamira Therapeutics's Asset Impairment Charge for the six months ended in Dec. 2023 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.


Altamira Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Altamira Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Asset Impairment Charge Chart

Altamira Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.66 13.31 -

Altamira Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Altamira Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.


Altamira Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics (Altamira Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.

Altamira Therapeutics (Altamira Therapeutics) Headlines

From GuruFocus

Altamira Therapeutics Provides Business Update

By Stock market mentor Stock market mentor 01-27-2023

Altamira Therapeutics Announces Reverse Stock Split

By Value_Insider Value_Insider 10-24-2022

Altamira Therapeutics Provides Year-End 2022 Business Update

By Value_Insider Value_Insider 12-19-2022